GlassScriptPhysician profile
Nisha Mohindra
NPI 1962635110
$67,466.44
in general payments reported to CMS, 2019-2025
22 companies · $18K in 2025
The $18K reported for 2025 was more than what 87% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,733 · 2021: $1,392 · 2022: $20K · 2023: $6,854 · 2024: $16K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Honoraria: $3,255 · Food and Beverage: $2,402 · Travel and Lodging: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,023.38 |
| Honoraria | $3,255.00 |
| Food and Beverage | $2,401.78 |
| Travel and Lodging | $1,207.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $18,345.00 | 2022-2025 | Zepzelca |
| E.R. Squibb & Sons, L.L.C. | $13,930.49 | 2019-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $10,810.60 | 2021-2025 | Imfinzi, Tagrisso |
| Regeneron Healthcare Solutions, INC. | $7,542.24 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $6,118.25 | 2019-2024 | Alecensa, Tecentriq |
| Regeneron Pharmaceuticals, INC. | $2,901.50 | 2022 | |
| Merck Sharp & Dohme LLC | $2,606.56 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $2,126.11 | 2025 | Gavreto |
| Amgen INC. | $1,715.00 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $1,200.00 | 2025 | |
| Bard Peripheral Vascular, INC. | $58.16 | 2025 | Pleurx |
| G1 Therapeutics, INC. | $46.74 | 2022 | |
| Emd Serono, INC. | $24.95 | 2022 | |
| Lilly USA, LLC | $24.06 | 2019 | |
| Tempus Ai, INC | $16.78 | 2025 | Xt Cdx |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Mohindra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.